Table 3.
Hazard Ratios Per 2‐Fold Higher Value of NT‐proBNP, Calculated Using a Joint Model: Stratified Analysis in Patients With Baseline BNP <14 pmol/L (Normal) and >14 pmol/L (Elevated)
| Baseline NT‐proBNP <14 pmol/L (Normal, n=280) | Baseline NT‐proBNP >14 pmol/L (Elevated, n=315) | |||||
|---|---|---|---|---|---|---|
| No. Cases | Crude HR (95% CI) | P Value | No. Cases | Crude HR (95% CI) | P Value | |
| Primary end point | 50 | 149 | ||||
| Repeated NT‐proBNP measurementsa | 1.61 (1.10–2.52) | 0.011 | 1.65 (1.46–1.86) | <0.001 | ||
| Adjusted for baseline NT‐proBNPb | 2.03 (0.88–4.71) | 0.098 | 2.08 (1.31–3.87) | <0.001 | ||
| Secondary end point | 2 | 56 | ||||
| Repeated NT‐proBNP measurementsa | 3.67 (0.41–63.2) | 0.284 | 2.30 (1.89–2.86) | <0.001 | ||
| Adjusted for baseline NT‐proBNPb | 6.62 (0.10–1026) | 0.435 | 2.47 (1.13–5.70) | 0.017 | ||
CI indicates confidence interval; HR, hazard ratio; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.
a
HR for a patient with a 2‐fold higher NT‐proBNP level than another patient at any point in time during the follow‐up.
b
HR for a patient with a 2‐fold higher NT‐proBNP level than another patient at any point in time during the follow‐up, when two patients with the same baseline NT‐proBNP level are compared.